Purpose of Review Glaucoma remains a prevalent disorder and visual limiting factor after Boston keratoprosthesis type 1 implantation. In addition, there are no standard guidelines for glaucoma surveillance and monitoring after keratoprosthesis surgery. This report provides a review of the current literature and offers innovative strategies that will overcome the challenges in managing glaucoma in the setting of a Boston keratoprosthesis type 1 implant. Recent Findings Patients with glaucoma have worse initial and late visual acuity outcomes after otherwise successful keratoprosthesis implantation. Management of glaucoma in the setting of a keratoprosthesis is challenging because of relatively rapid progression and an inability to accurately measure intraocular pressure (IOP). The topics that will be discussed in this section include alternative methods for IOP measurement, rationales and surgical techniques for a pars plana tube placement for glaucoma drainage device, effective medical and laser treatments, the risk for IOP elevations after YAG laser, and practical guides to glaucoma surveillance and monitoring. Summary Management of glaucoma in Boston type 1 keratoprosthesis remains a challenge. In eyes with preexisting glaucoma, glaucoma drainage device before or at the time of keratoprosthesis should be performed. Most importantly, early detection and prompt treatment of IOP elevations and glaucoma progression is required to prevent poor visual outcomes.
Introduction
Glaucoma remains a prevalent disorder and visual limiting factor after Boston keratoprosthesis type 1 implantation. The majority of eyes with Boston type 1 keratoprosthesis suffer from glaucoma, with the overall prevalence ranging from 64 to 84 % [1] [2] [3] [4] . Among this population, the prevalence of preexisting glaucoma ranges from 36 to 78 %, while the incidence of postoperative intraocular pressure (IOP) elevation and/or glaucoma ranges from 8 to 35 % per year [2-4, 5 •• , 6, 7, 8 • , 9, 10 •• , [11] [12] [13] [14] . Importantly, glaucoma negatively impacts both initial and late visual outcomes after otherwise successful keratoprosthesis implantation. Specifically, a recent report by Kamyar et al. showed that eyes with preexisting glaucoma have worse initial best-corrected visual acuity, compared to those without glaucoma after Boston keratoprosthesis type 1 (3/ 200 vs. 20/563) [8 • ]. Furthermore, Talajic et al. reported that 13 % of eyes post keratoprosthesis implantation lost fixation from glaucoma after experiencing an initial dramatic improvement in visual acuity, and 21 % had documented visual field progression and/or needed glaucoma surgery during a 16-month follow-up period [15 • ]. Consistently, Crnej et al. reported a similar rate of glaucoma progression of 21 % annually based on data from a large series with relatively long follow-up (106 eyes during a 3.3-year follow-up period) [ 
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& Thasarat S. Vajaranant tvajaranant@yahoo.com Management of glaucoma in the setting of a keratoprosthesis is challenging because of relatively rapid progression and an inability to accurately measure IOP. In addition, there are no standard guidelines for glaucoma surveillance and monitoring in keratoprosthesis. This report provides a review of current literature, clinical pearls, and innovative strategies to assist in overcoming the challenges in monitoring and treating glaucoma in the setting of a Boston keratoprosthesis type 1 implant.
Alternative Methods for IOP Measurement in Boston Type 1 Keratoprosthesis
The main treatment goal of glaucoma is to control IOP; therefore, an accurate measurement of IOP is vital. However, as most tonometers are designed to measure IOP through the central cornea, it is impossible to measure IOP through the prosthetic cornea. As a result, most surgeons rely on tactile IOP which was reported to be useful for identifying an IOP of 30 mmHg or greater [16] . In addition to tactile IOP, alternative methods for measurement include scleral pneumatonometry (Mentor, Inc., Norwell, Massachusetts, USA) [17 • ] and transpalpebral (Diaton, BiCOM, Inc., Long Beach, NY, USA) tonometry. Based on our study comparing central corneal and scleral pneumatonometry in 97 healthy eyes [17 • ], we found three important observations; (1) corneal and scleral pneumatonometry positively correlate, (2) a scleral IOP consistently reads higher than a corneal IOP, and (3) the scleral IOP reading is more accurate at the lower level of IOP. Practically, scleral pneumatometry can be used in eyes with keratoprosthesis, and it is confirmative if the scleral IOP reading is within a normal range. Furthermore, we reported agreement among transpalpebral, transscleral, and tactile IOP measurements in 23 eyes with Boston type 1 keratoprosthesis [18] . Our data suggest that transscleral measurements by pneumatonometer yield higher readings compared to tactile and transpalbebral IOP measurements. The percentage agreement, defined as readings within 2 mmHg, was highest between tactile and transpalpebral methods (95 %), compared to the percentage agreement between tactile range and transscleral IOP (85 %) and transpalpebral and transscleral IOP (48 %) [18] .
Clinical Pearls
Alternative IOP measurements through the sclera and an eyelid should be considered as a confirmatory method in addition to routine tactile IOP in eyes with Boston type 1 keratoprosthesis.
Why Consider a Combined Glaucoma Drainage Device at the Time of Keratoprosthesis Implantation?
As mentioned previously, the overall prevalence of glaucoma is high in eyes with Boston type 1 keratoprosthesis [2-4, [3, 4] . Notably, a series reporting a higher rate of prior and/or combined glaucoma surgery at the time of keratoprosthesis implantation had a lower rate of subsequent glaucoma surgery compared to the other [3, 4] . In our early series of 70 eyes between 2006 and 2010, with a follow-up time on average of 14.7 ± 11.4 months, the prevalence of preexisting glaucoma is 70 % [19] . Figure 1 shows a diagram of glaucoma prevalence and incidence of IOP elevation that required treatment in eyes with or without preexisting glaucoma and with or without prior or combined glaucoma surgery. One third of patients without preexisting glaucoma developed an IOP elevation that required treatment (29 %) [19] . Eyes with preexisting glaucoma had a twice higher rate of postoperative IOP elevations that required treatment (58 vs. 29 %) [19] . In eyes with preexisting glaucoma, the rate of IOP elevation that required treatment was higher in eyes without prior/combined shunt compared to eyes with prior/combined shunt (66 vs. 45 %) [19] . Accordingly, 
These data suggest that performing a combined glaucoma shunt procedure at the time of keratoprosthesis lowers the rate of subsequent IOP elevation and/or glaucoma surgery in eyes with preexisting glaucoma regardless of preoperative IOP. However, there is not enough evidence to support combined glaucoma surgery at the time of keratoprosthesis implantation in eyes without preexisting glaucoma. Further analysis with longer-term follow-up is needed to address this issue.
The Art of Glaucoma Surgery in Eyes with Boston Type 1 Keratoprosthesis
For a successful glaucoma drainage device implantation in eyes with Boston type 1 keratoprosthesis, there are two important considerations: (1) the position of tube placement and (2) the necessity for optimal postoperative contact lens fitting to maintain corneal hydration and postoperative best-corrected visual acuity [20, 21] .
With regards to optimal tube position, pars plana insertion is preferred for a number of reasons [20, 22 • ]. First, there is limited space in the anterior chamber after keratoprosthesis surgery, and a functional anterior chamber depth is on average less than 1 mm in both pseudophakic and phakic eyes (Fig. 2) . Specifically, average anatomical anterior chamber depth is 2 mm, whereas average functional anterior chamber depth is 0. 20, 21] .
Eyes that require keratoprosthesis often have compromised or scared conjunctiva secondary to poor ocular surface and/or previous surgery [20] . As a result, these eyes are prone to glaucoma drainage device-related complications such as implant exposure. The incidence of glaucoma implant exposure after Boston type 1 keratoprosthesis varies and ranges from none in 18 eyes during 21.5 months to 9 in 25 eyes during 33.6 months based on previous reports (0-12 % annually) [26, 27] . In comparison, the incidence of tube exposure in the tube versus trab study is 6 % in 5 years (1.2 % annually) [28] . Based on the higher thesis, it is essential to use patch graft reinforcement of the tube to prevent exposure. The preferred choice of patch graft in a combined case is a corneal or corneoscleral patch graft. The corneal patch graft can be obtained from the recipient or preserved donor graft, whereas the corneoscleral patch graft can be prepared from a rim of the same donor tissue used for the keratoprosthesis. The key to optimal contact lens fitting is to use a thin patch graft with a corneal side covering the tube entry. In some cases, a careful preparation of the patch graft is necessary. For example, if the patch is too thick or bulky, one might consider to perform a lamellar dissection of the patch graft and/or to create a slope on an anterior edge of the patch graft. (3) Conjunctival closure the least tension is preferred to promote optimal conjunctival closure and proper healing. Blunt dissection of the conjunctival flap might be necessary in some cases. In eyes with inadequate conjunctival closure, it is much preferred to use a corneal patch graft and bring the edge of the conjunctiva to cover all edges of the patch graft. This will allow conjunctival epithelization over the corneal patch graft. In addition, it is important to consider a complete ligation of the tube in this case to allow maximal time to conjunctival healing to ensure a watertight closure. Lastly, consider using an amniotic membrane and fibrin glue in difficult conjunctival closure.
In our series of eyes with pars plana tube insertion [22 • ], 1 in 20 eyes experienced exposure during 31.6 months follow-up time on average. In this case, the exposure was thought to be due to a bulky scleral patch graft and pars plana clip. After we adopted the above techniques, there was no reported tube exposure in our series. In addition, during follow-up, the majority of eyes had normal tactile IOP (85 %) and optimal contact lens fitting (75 %). Twenty percent required subsequent glaucoma procedures to further control IOP and two eyes required explantation due to endophthalmitis that was not related to glaucoma implants.
Clinical Pearls
Pars plana tube insertion, careful preparation of patch graft, and meticulous conjunctival closure in eyes with Boston type 1 keratoprosthesis are essential to ensure the optimal IOP control with decreased risk of device-related complications.
Effective Medical and Laser Treatment for Glaucoma in Eyes with Boston Type 1 Keratoprosthesis
For medical therapy, both topical and oral IOP-lowering agents can be used. In theory, topical medications could still be absorbed through the recipient/donor corneas as well as through the sclera. Clinical pearls for selecting IOP-lowering agents are as follows:
(1) Based on the mechanism of action, an aqueous suppressant and medications that improve uveoscleral outflow are most likely superior to medications that target the trabecular meshwork as the majority of these eyes often have extensive angle closure. (2) As many of these eyes also suffer from chronic and/or chronic cystoid macular edema, prostaglandins should be avoided or stopped [29] . (3) Steroid response may also be a cause of increased IOP in the eyes with an open angle [30] . However, in eyes with complete angle closure, steroid does not likely affect the IOP. In the case of steroid response, tapering steroid and/or changing a potent to a less potent steroid may reverse the steroid response. (4) To promote a healthy ocular surface and to ensure adequate hydration between a prosthesis and donor cornea junction, fixed-combination, benzalkonium chloride-free and/or preservative-free agents should be considered. (5) Oral carbonic anhydrase inhibitors (CAIs) such as acetazolamide and methazolamide may be used with caution after reviewing a history of kidney function and allergy. For a long-term use of oral CAI, a primary physician should be consulted and involved in a long-term care and monitoring of its side effects. Special caution should also be taken in patients who reported a history of Stevens-Johnson syndrome from a sulfa allergy. However, a previous report showed that when acetazolamide or furosemide was challenged in patients with idiopathic intracranial hypertension, who had a history of sulfa allergy, none of 34 patients demonstrated a true allergic reaction from a potential cross-reaction between sulfa and acetazolamide [31] .
For laser treatment for glaucoma in Boston keratoprosthesis type 1, a recent study by Rivier et al. suggested that transscleral cyclophotocoagulation could be performed as an adjunct therapy for IOP control in Boston type 1 keratoprosthesis. They found a significantly decreased IOP after laser without a significant change in final visual acuity, in 18 eyes during a mean follow-up of 26.6 ± 19.6 months [32] . Furthermore, 33.3 % required additional laser, and 11 % required more than two sessions [32] . In this series, complications included one case of conjunctival dehiscence and the other with fungal endophthalmitis [32] .
Clinical Pearls
Topical and oral antiglaucoma medications and cyclophotocoagulation could be used in eyes with Boston type 1 keratoprosthesis with caution.
The Risk for IOP Elevations After YAG Laser
The risk for an immediate postoperative IOP elevation after YAG capsulotomy is well recognized. However, the risk for a long-term effect of YAG laser on IOP is not widely known. Based on a retrospective review of 69 glaucoma patients who underwent YAG capsulotomy, 38.1 % had disease progression which was defined as increased IOP of greater than 5 mmHg on two consecutive visits, addition of antiglaucoma medications or subsequent glaucoma surgery at 12 months [33, 34] . In eyes with Boston type 1 keratoprosthesis, YAG capsulotomy for posterior capsule opacity and/or YAG membranectomy for a retroprosthetic membrane are often needed. In addition, repeated procedures and a high energy are often required. It is therefore conceivable that the YAG laser may lead to undetected IOP elevations and perhaps a long-term instability of IOP control in eyes with glaucoma. As IOP cannot be accurately measured in eyes with keratoprostheses, pretreatment with topical and/or oral antiglaucomatous medications for YAG laser in eyes with keratoprosthesis should be considered. In addition, careful monitoring of IOP and glaucoma progression after YAG laser treatment is recommended.
Clinical Pearls
Pretreatment for YAG laser to prevent IOP immediate postoperative IOP elevations and careful monitoring of IOP and glaucoma progression are recommended.
Practical Guides to Glaucoma Surveillance and Monitoring in Eyes with Boston Type 1 Keratoprosthesis
Glaucoma is the most common of irreversible visual loss in eyes with Boston type 1 keratoprosthesis. Hence, glaucoma surveillance in eyes without preexisting glaucoma and glaucoma monitoring in eyes with preexisting glaucoma after Boston type 1 keratoprosthesis are essential to prevent permanent blindness.
Surveillance for De Novo Glaucoma
As the incidences of IOP elevation and glaucoma are high among eyes without preexisting glaucoma (8-35 % annually) [2-4, 5 •• , 6, 7, 8 • , 9, 10 •• , [11] [12] [13] [14] . Surveillance of glaucoma is necessary. Practically, these eyes should be considered glaucoma suspects and/or high risk, and it is therefore recommended to establish a baseline for IOP measurement, visual field, and imaging of the optic nerve and optical coherence tomography of the anterior segment and optic nerve. Figure 3 shows visual field, optic nerve photographs, and imaging. Notably, a previous report demonstrated that reliable visual field tests could be obtained in only 59 %; therefore, it is advised to use structural measures, the main outcome measure [5 •• ] . The causes of de novo IOP elevations and glaucoma are multifactorial, and the main causes are likely progressive angle closure, steroid response, or a combination. As previously documented, progressive angle closure can occur within 6 months postoperatively in eyes without preoperative angle closure [24 • ]. Chronic angle closure that progresses slowly may potentially lead to progressive glaucomatous damage without accompanying acute pain or symptoms. In addition, as topical steroid is commonly used after a corneal transplantation, these eyes are at risk for IOP elevation. In the normal population, the incidence of IOP elevation after a topical steroid use is approximately 30 % [30] . Depending on the baseline IOP, the steroid response may lead to a significant IOP elevation with subsequent optic nerve damage and permanent visual loss. In practice, IOP measurement should be documented on each visit, while visual field testing and optic nerve imaging should be alternately performed every 6 months.
Monitoring for Glaucoma Progression
In eyes with glaucoma, careful monitoring of IOP elevation and glaucoma progression is extremely important to prevent permanent visual loss for two main reasons. First, the incidence of progression is high (21 % annually). Furthermore, the incidence of IOP elevations required treatment is twice higher in eyes with glaucoma compared to those without (58 vs. 29 %) [19] . Second, rapid progression and losses of fixation may occur in the eyes with preexisting glaucoma as many of them often have limited outflow facility from extensive angle closure and underlying advanced optic nerve damage. Accordingly, frequent follow-up is often required to detect any glaucoma progression. It is advised to perform IOP measurements at every visit (every 3-4 months), while visual fields and optic nerve photographs and imaging may be alternately performed every 6 months. Given the potentially aggressive nature of glaucomatous progression in eyes with keratoprosthesis, prompt treatment is needed in eyes with IOP elevations and/or suspicious glaucoma progression.
Clinical Pearls
Early detection for IOP elevations and/or glaucoma progression requires regular surveillance and frequent followup. Low-threshold and prompt treatment are necessary to prevent permanent visual loss from glaucoma in eyes with Boston type 1 keratoprosthesis.
In conclusion, management of glaucoma in Boston type 1 keratoprosthesis remains a challenge because of the high prevalence of glaucoma, fast progression, and an inability to measure IOP. In eyes with preexisting glaucoma, glaucoma drainage device before or at the time of keratoprosthesis should be performed. Most importantly, early detection and prompt treatment of IOP elevations and glaucoma progression is required to prevent poor visual outcomes. 
